The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Securopen     (2R,5R,6S)-3,3-dimethyl-7- oxo-6-[[2-[(2...

Synonyms: Azlocilina, azlocillin, Azlin, Azlocilline, Azlocillinum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of azlocillin


Psychiatry related information on azlocillin

  • Although the mean levels suggest a remarkable penetration of azlocillin into chondral tissue, the high individual differences observed in the tissue levels (2.1 to 138 micrograms/g tissue) require a higher dosage to ensure sufficient antimicrobial therapy in all patients [6].

High impact information on azlocillin


Chemical compound and disease context of azlocillin


Biological context of azlocillin


Anatomical context of azlocillin


Associations of azlocillin with other chemical compounds


Gene context of azlocillin

  • In the piperacillin and azlocillin series, there was good binding to PBP 3 of E. coli (0.1 microgram/ml) and PBPs 1, 2, and 3 of S. aureus (approximately 1 microgram/ml) [13].
  • The ability of combinations of azlocillin and tobramycin to prevent or delay resistance development in eight Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients was studied using chequerboard titration and in-vitro serial subculture [29].
  • Pulmonary function and microbiological responses were similar in the three treatment groups, although patients receiving azlocillin and placebo tended to have a smaller reduction in the concentration of bacteria in the sputum and a greater rate of acquisition of antibiotic-resistant organisms [30].
  • The binding affinity delta F degree for the interaction between azlocillin and mezlocillin to human albumin is equal to -15,389 J/mol [31].
  • The therapeutic effects of cefoperazone, azlocillin, and piperacillin were much less than expected from their in vitro antibacterial activities; the CD50 values were more than 18-fold as large as that of cefsulodin, whereas the differences of their MIC values were less than four-fold [32].

Analytical, diagnostic and therapeutic context of azlocillin


  1. In-vitro activity of azlocillin against Pseudomonas. Chattopadhyay, B., Hall, I. Lancet (1979) [Pubmed]
  2. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Bosso, J.A., Black, P.G., Matsen, J.M. Am. J. Med. (1987) [Pubmed]
  3. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Johnson, D.E., Thompson, B. Am. J. Med. (1986) [Pubmed]
  4. In vitro activity and in vivo evaluation of ticarcillin plus clavulanic acid against aerobic and anaerobic bacteria. Bansal, M.B., Chuah, S.K., Thadepalli, H. Am. J. Med. (1985) [Pubmed]
  5. Quality control and interpretive criteria for the azlocillin disk diffusion susceptibility test. Fass, R.J. Antimicrob. Agents Chemother. (1982) [Pubmed]
  6. Concentration of azlocillin in human chondral tissue. Schönfeld, W., Knöller, J., Bremm, K.D., Meier, H., König, W. Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology. (1988) [Pubmed]
  7. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. Moody, J.A., Gerding, D.N., Peterson, L.R. Am. J. Med. (1987) [Pubmed]
  8. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function. Kampf, D., Borner, K., Möller, M., Kessel, M. Clin. Pharmacol. Ther. (1984) [Pubmed]
  9. Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Danelon, C., Nestorovich, E.M., Winterhalter, M., Ceccarelli, M., Bezrukov, S.M. Biophys. J. (2006) [Pubmed]
  10. Structure-activity relationships of different beta-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase. Hujer, A.M., Kania, M., Gerken, T., Anderson, V.E., Buynak, J.D., Ge, X., Caspers, P., Page, M.G., Rice, L.B., Bonomo, R.A. Antimicrob. Agents Chemother. (2005) [Pubmed]
  11. Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa. McFarland, M.M., Scott, E.M., Li Wan Po, A. Antimicrob. Agents Chemother. (1994) [Pubmed]
  12. In vitro models for the study of combination antibiotic therapy in neutropenic patients. Zinner, S.H., Dudley, M., Blaser, J. Am. J. Med. (1986) [Pubmed]
  13. Binding of monobactams to penicillin-binding proteins of Escherichia coli and Staphylococcus aureus: relation to antibacterial activity. Georgopapadakou, N.H., Smith, S.A., Cimarusti, C.M., Sykes, R.B. Antimicrob. Agents Chemother. (1983) [Pubmed]
  14. Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Phaneuf, D., Neu, H.C. Antimicrob. Agents Chemother. (1979) [Pubmed]
  15. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Bustamante, C.I., Wharton, R.C., Wade, J.C. Antimicrob. Agents Chemother. (1990) [Pubmed]
  16. Effect of aztreonam in combination with azlocillin or piperacillin on Pseudomonas aeruginosa. Wu, D.H., Baltch, A.L., Smith, R.P., Conley, P.E. Antimicrob. Agents Chemother. (1984) [Pubmed]
  17. Pharmacokinetics of azlocillin in subjects with normal and impaired renal function. Leroy, A., Humbert, G., Godin, M., Fillastre, J.P. Antimicrob. Agents Chemother. (1980) [Pubmed]
  18. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. McLaughlin, F.J., Matthews, W.J., Strieder, D.J., Sullivan, B., Taneja, A., Murphy, P., Goldmann, D.A. J. Infect. Dis. (1983) [Pubmed]
  19. Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa. White, A.R., Comber, K.R., Sutherland, R. Antimicrob. Agents Chemother. (1980) [Pubmed]
  20. Prolonged bleeding time during azlocillin therapy. Dijkmans, B.A., Van Der Meer, J.W., Boekhout-Mussert, M.J., Zaal-De Jong, M., Mattie, H. J. Antimicrob. Chemother. (1980) [Pubmed]
  21. Materno-fetal transfer of azlocillin. Kafetzis, D.A., Brater, D.C., Fanourgakis, J.E. J. Antimicrob. Chemother. (1983) [Pubmed]
  22. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Scribner, R.K., Marks, M.I., Weber, A.H., Tarpay, M.M., Welch, D.F. Antimicrob. Agents Chemother. (1982) [Pubmed]
  23. The tolerance and safety of azlocillin. Parry, M.F. J. Antimicrob. Chemother. (1983) [Pubmed]
  24. Comparative pharmacokinetics of azlocillin and piperacillin in normal adults. Colaizzi, P.A., Polk, R.E., Poynor, W.J., Raffalovich, A.C., Cefali, E.A., Beightol, L.A. Antimicrob. Agents Chemother. (1986) [Pubmed]
  25. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Chalkley, L.J., Koornhof, H.J. Antimicrob. Agents Chemother. (1985) [Pubmed]
  26. A comparison of azlocillin and gentamicin in the treatment of serious infections caused by Pseudomonas aeruginosa. Gonzalez, M.A. J. Antimicrob. Chemother. (1983) [Pubmed]
  27. Comparative in-vitro activity of ciprofloxacin against non-fermenters. Husson, M.O., Izard, D., Bouillet, L., Leclerc, H. J. Antimicrob. Chemother. (1985) [Pubmed]
  28. Improved procedure for the determination of the ureidopenicillins azlocillin and mezlocillin plasma by high-performance liquid chromatography. Hildebrandt, R., Gundert-Remy, U. J. Chromatogr. (1982) [Pubmed]
  29. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. Wu, Y.L., Scott, E.M., Po, A.L., Tariq, V.N. J. Antimicrob. Chemother. (1999) [Pubmed]
  30. Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis. McLaughlin, F.J., Matthews, W.J., Strieder, D.J., Sullivan, B., Goldmann, D.A. J. Antimicrob. Chemother. (1983) [Pubmed]
  31. Comparative study of the binding of acylureidopenicillins and carbenicillin to human serum proteins. Rosenkranz, H., Förster, D. Infection (1979) [Pubmed]
  32. Relevance of in vitro antibacterial activities and pharmacokinetic properties of antipseudomonal beta-lactam antibiotics to their therapeutic effects on urinary tract infection caused by Pseudomonas aeruginosa P 9 in mice. Nakao, M., Nishi, T., Kondo, M., Fugono, T., Imada, A., Tsuchiya, K. J. Antibiot. (1984) [Pubmed]
  33. Intravenous azlocillin kinetics in patients on long-term hemodialysis. Aletta, J.M., Francke, E.F., Neu, H.C. Clin. Pharmacol. Ther. (1980) [Pubmed]
  34. High-pressure liquid chromatographic quantitation of azlocillin. Weber, A., Opheim, K.E., Wong, K., Smith, A.L. Antimicrob. Agents Chemother. (1983) [Pubmed]
  35. Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers. Lander, R.D., Henderson, R.P., Pyszczynski, D.R. Antimicrob. Agents Chemother. (1989) [Pubmed]
  36. Effect of azlocillin on uric acid levels in serum. Ernst, J.A., Sy, E.R. Antimicrob. Agents Chemother. (1983) [Pubmed]
WikiGenes - Universities